Publications by authors named "L Sidur"
Br J Dermatol
October 2021
Article Synopsis
- Adalimumab shows significant effectiveness in treating hidradenitis suppurativa (HS), with over 50% of patients achieving a clinical response by week 12 and maintaining it for up to 168 weeks, as highlighted in the PIONEER trials.
- The study explored potential biomarkers that could predict the effectiveness of adalimumab, using plasma samples from patients at baseline and after 12 weeks of treatment.
- Findings indicated that higher levels of certain proteins (hs-CRP and CCL16) in nonresponders and a predictive response signature (involving calprotectin, fractalkine, and HCC-4) could help identify patients likely to benefit from adalimumab, while also suggesting that
